The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Abuzarova G.R.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center;
Russian Medical Academy of Continuous Professional Education

Sarmanaeva R.R.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center;
Russian Medical Academy of Continuous Professional Education

Germanova O.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy

Authors:

Abuzarova G.R., Sarmanaeva R.R., Germanova O.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2024;13(5): 76‑81

DOI: 10.17116/onkolog20241305176

Views: 278

Downloaded: 2

Buy for 200₽
Contact the author
Table of contents

To cite this article:

Abuzarova GR, Sarmanaeva RR, Germanova OV. Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy. P.A. Herzen Journal of Oncology. 2024;13(5):76‑81. (In Russ.)
https://doi.org/10.17116/onkolog20241305176

Подписка 2025 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Rela­pse of primary mediastinal B-cell lymphoma with isolated central nervous system invo­lvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Onco­logy. 2024;(2):39-45
The use of Mexi­dol in patients with mild (moderate) cognitive impairment: resu­lts of a meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):82-88
Successful combinations of drug and non-drug therapy for low back pain. Russian Journal of Pain. 2024;(1):57-67
Respiratory-syncitial virus: biology, gene­tic dive­rsity and perspective control preparations. Mole­cular Gene­tics, Microbiology and Viro­logy. 2024;(1):16-24
Pathogenetic, clinical-diagnostic and therapeutic aspe­cts of premenstrual syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):37-42
Clinical, demo­graphic, anamnestic and instrumental data of patients with acute coro­nary syndrome and Covid-19. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):204-209
Traumatic damage to the diaphragm in children. Piro­gov Russian Journal of Surgery. 2024;(4):64-68
Promising approaches to the pathogenetic therapy of amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21
Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68
Cognitive impairment in cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a significant problem in oncology, which greatly worsens the quality of life of patients and is the reason for the reduction or cancellation of cancer therapy. The review presents the pathophysiological features of the development of CIPN, describes the features of the diagnosis of CIPN, risk factors for its development, prevention and treatment. In addition to the only currently approved ASCO duloxetine, the results of clinical studies confirming the therapeutic effect of a central analgesic with a mixed mechanism of action, tapentadol, comparable to duloxetine, are presented

Keywords:

CIPN
clinical outcomes
mechanism
treatment
tapentadol

Authors:

Abuzarova G.R.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center;
Russian Medical Academy of Continuous Professional Education

Sarmanaeva R.R.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center;
Russian Medical Academy of Continuous Professional Education

Germanova O.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Received:

10.09.2024

Accepted:

13.09.2024

List of references:

  1. Brayall P, Donlon E, Doyle L, Leiby R, Violette K. Physical therapy-based interventions improve balance, function, symptoms, and quality of life in patients with chemotherapy-induced peripheral neuropathy: a systematic review. Rehabil Oncol. 2021;36(3):161-166.  https://doi.org/10.1097/01.REO.0000000000000111
  2. Papadopoulou M, Stamou M, Bakalidou D, Moschovos C, Zouvelou V, Zis P, Tzartos J, Chroni E, Michopoulos I, Tsivgoulis G. Non-pharmacological interventions on pain and quality of life in chemotherapy induced polyneuropathy: systematic review and meta-analysis. In Vivo. 2023;37(1):47-56.  https://doi.org/10.21873/invivo.13053
  3. De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol. 2015;96(1):34-45.  https://doi.org/10.1016/j.critrevonc.2015.04.011
  4. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. https://doi.org/10.1016/j.pain.2014.09.020
  5. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9-17.  https://doi.org/10.1007/PL0000785
  6. Tikhonova OA, Druzhinin DS, Tynterova AM, Reverchuk IV. Sovremennoe predstavlenie o khimioindutsirovannoi polineiropatii (obzor literatury). Nervno-myshechnye Bolezni. 2023;13(1):10-21. (In Russ.). https://doi.org/10.17650/2222-8721-2023-13-1-10-21
  7. Boyette-Davis J, Xin W, Zhang H. Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011;152(2):308-313.  https://doi.org/10.1016/j.pain.2010.10.030
  8. Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2019;17(2):184-196.  https://doi.org/10.2174/1570159X15666170915143217
  9. Zhang H, Dougherty PM. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology. 2014;120(6):1463-1475. https://doi.org/10.1097/ALN.0000000000000176
  10. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988;48(23):6876-6881.
  11. Brown DC, Iadarola MJ, Perkowski SZ, Erin H, Shofer F, Laszlo KJ, Olah Z, Mannes AJ. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology. 2005;103(5):1052-1059. https://doi.org/10.1097/00000542-200511000-00020
  12. Nassini R, Gees M, Harrison S, et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain. 2011;152(7):1621-1631. https://doi.org/10.1016/j.pain.2011.02.051
  13. Sittl R, Lampert A, Huth T, Schuy ET, Link AS, Fleckenstein J, Alzheimer C, Grafe P, Carr RW. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A. 2012;109(17):6704-6709. https://doi.org/10.1073/pnas.1118058109
  14. Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain. 2010;6:15.  https://doi.org//10.1186/1744-8069-6-15
  15. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience. 2007;144(2):714-720.  https://doi.org/10.1016/j.neuroscience.2006.09.044
  16. Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med. 2008;14(3):331-336.  https://doi.org/10.1038/nm1723
  17. Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3-9.  https://doi.org//10.1016/j.cyto.2012.03.027
  18. Schäfers M, Sorkin L. Effect of cytokines on neuronal excitability. Neurosci Lett. 2008;437(3):188-193.  https://doi.org/10.1016/j.neulet.2008.03.052
  19. Butturini E, Carcereri de Prati A, Chiavegato G, Rigo A, Cavalieri E, Darra E, Mariotto S. Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs. Free Radic Biol Med. 2013;65:1322-1330. https://doi.org/10.1016/j.freeradbiomed.2013.09.015
  20. Materazzi S, Fusi C, Benemei S, Pedretti P, Patacchini R, Nilius B, Prenen J, Creminon C, Geppetti P, Nassini R. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pflugers Arch. 2012;463(4):561-569.  https://doi.org/10.1007/s00424-011-1071-x
  21. Musatov A, Robinson NC. Susceptibility of mitochondrial electron-transport complexes to oxidative damage. Focus on cytochrome c oxidase. Free Radic Res. 2012;46(11):1313-1326. https://doi.org/10.3109/10715762.2012.717273
  22. Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain. 2012;13(3):276-284.  https://doi.org/10.1016/j.jpain.2011.11.009
  23. Doyle T, Chen Z, Muscoli C, et al. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J Neurosci. 2012;32(18):6149-6160. https://doi.org/10.1523/JNEUROSCI.6343-11.2012
  24. Sawicka E, Długosz A, Rembacz KP, Guzik A. The effects of coenzyme Q10 and baicalin in cisplatin-induced lipid peroxidation and nitrosative stress. Acta Pol Pharm. 2013;70(6):977-985. 
  25. Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007;1168:46-59.  https://doi.org/10.1016/j.brainres.2007.06.066
  26. Luiz AP, MacDonald DI, Santana-Varela S, Millet Q, Sikandar S, Wood JN, Emery EC. Cold sensing by NaV1.8-positive and NaV1.8-negative sensory neurons. Proc Natl Acad Sci U S A. 2019;116(9):3811-3816. https://doi.org/10.1073/pnas.1814545116
  27. MacDonald DI, Luiz AP, Iseppon F, Millet Q, Emery EC, Wood JN. Silent cold-sensing neurons contribute to cold allodynia in neuropathic pain. Brain. 2021;144(6):1711-1726. https://doi.org/10.1093/brain/awab086
  28. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9-17.  https://doi.org/10.1007/PL00007853
  29. Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451
  30. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon MT. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. https://doi.org/10.1016/j.pain.2014.09.020
  31. Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain. 2019;160(Suppl. 1):S1-S10.  https://doi.org/10.1097/j.pain.0000000000001540
  32. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998;9(7):739-744.  https://doi.org/10.1023/a:1008344507482
  33. Cho Y, Ruddy KJ, Lavoie Smith EM. Evaluation of chemotherapy-induced peripheral neuropathy. In: Lustberg M, Loprinzi C, eds. Diagnosis, management and emerging strategies for chemotherapy-induced neuropathy. Springer Cham; 2021;53-93.  https://doi.org/10.1007/978-3-030-78663-2_3
  34. Smith EM, Beck SL, Cohen J. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008;35(1):96-102.  https://doi.org/10.1188/08.ONF.96-102
  35. Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, Friedlander M. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol. 2017;28(11):2733-2740. https://doi.org/10.1093/annonc/mdx491
  36. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13(6):741-748.  https://doi.org/10.1111/j.1525-1438.2003.13603.x
  37. Le-Rademacher J, Kanwar R, Seisler D, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer. 2017;25(11):3537-3544. https://doi.org/10.1007/s00520-017-3780-y
  38. Li T, Timmins HC, Trinh T, et al. Patient-reported outcome measures in chemotherapy-induced peripheral neurotoxicity: defining minimal and clinically important changes. J Natl Compr Canc Netw. 2023;21(2):125-132.e3.  https://doi.org/10.6004/jnccn.2022.7074.
  39. Pérez C, Sánchez-Martínez N, Ballesteros A, Blanco T, Collazo A, González F, Villoria J. Prevalence of pain and relative diagnostic performance of screening tools for neuropathic pain in cancer patients: a cross-sectional study. Eur J Pain. 2015;19(6):752-761.  https://doi.org/10.1002/ejp.598
  40. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92(1-2):147-157.  https://doi.org/10.1016/S0304-3959(00)00482-6
  41. Bechakra M, Nieuwenhoff MD, van Rosmalen J, Groeneveld GJ, Scheltens-de Boer M, Sonneveld P, van Doorn PA, de Zeeuw CI, Jongen JL. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Mol Pain. 2018;14:1744806918797042. https://doi.org/10.1177/1744806918797042
  42. Boyette-Davis J, Xin W, Zhang H, Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011;152(2):308-313.  https://doi.org/10.1016/j.pain.2010.10.030
  43. Boyette-Davis JA, Hou S, Abdi S, Dougherty PM. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018;8(5):363-375.  https://doi.org/10.2217/pmt-2018-0020
  44. Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, Lustberg MB. Updates in the treatment of chemotherapy-induced peripheral neuropathy. Curr Treat Options Oncol. 2022;23(1):29-42.  https://doi.org/10.1007/s11864-021-00926-0
  45. Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig. 2020;40(3):249-257.  https://doi.org/10.1007/s40261-019-00882-6
  46. Avan R, Janbabaei G, Hendouei N, Alipour A, Borhani S, Tabrizi N, Salehifar E. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: a randomized clinical trial. J Res Med Sci. 2018;23:52.  https://doi.org/10.4103/jrms.JRMS_1068_17
  47. Galiè E, Villani V, Terrenato I, Pace A. Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurol Sci. 2017;38(10):1747-1752. https://doi.org/10.1007/s10072-017-3035-1
  48. Sansone P, Giaccari LG, Aurilio C, Coppolino F, Passavanti MB, Pota V, Pace MC. Comparative efficacy of tapentadol versus tapentadol plus duloxetine in patients with chemotherapy-induced peripheral neuropathy (CIPN): a randomized non-inferiority clinical trial. Cancers (Basel). 2022;14(16):4002. https://doi.org/10.3390/cancers14164002
  49. Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med. 2014;44(9):1289-1304. https://doi.org/10.1007/s40279-014-0207-5
  50. Cunningham JE, Kelechi T, Sterba K, Barthelemy N, Falkowski P, Chin SH. Case report of a patient with chemotherapy-induced peripheral neuropathy treated with manual therapy (massage). Support Care Cancer. 2011;19(9):1473-1476. https://doi.org/10.1007/s00520-011-1231-8
  51. Klafke N, Bossert J, Kröger B, et al. Prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN) with non-pharmacological interventions: clinical recommendations from a systematic scoping review and an expert consensus process. Med Sci (Basel). 2023;11(1):15.  https://doi.org/10.3390/medsci11010015
  52. Izgu N, Ozdemir L, Bugdayci Basal F. Effect of aromatherapy massage on chemotherapy-induced peripheral neuropathic pain and fatigue in patients receiving oxaliplatin: an open label quasi-randomized controlled pilot study. Cancer Nurs. 2019;42(2):139-147.  https://doi.org/10.1097/NCC.0000000000000577
  53. Kanzawa-Lee GA, Larson JL, Resnicow K, Smith EML. Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review. Cancer Nurs. 2020;43(3):E172-E185. https://doi.org/10.1097/NCC.0000000000000801
  54. Gewandter JS, Chaudari J, Ibegbu C, et al. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Support. Care Cancer. 2019;27(5):1765-1774. https://doi.org/10.1007/s00520-018-4424-6
  55. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2005;32(2):305-311.  https://doi.org/10.1188/05.ONF.305-311

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.